We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.83%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.49B
AUM Growth
+$21.6M
Cap. Flow
+$155M
Cap. Flow %
6.21%
Top 10 Hldgs %
58.42%
Holding
119
New
16
Increased
22
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$27.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.7M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.2M
4
MDCO
Medicines Co
MDCO
+$16M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$14.8M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$37M
2
AVTR icon
Avantor
AVTR
+$16.9M
3
Z icon
Zillow
Z
+$13.9M
4
BPMC
Blueprint Medicines
BPMC
+$13M
5
HTHT icon
Huazhu Hotels Group
HTHT
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 49.17%
2 Consumer Discretionary 26.12%
3 Technology 2.9%
4 Communication Services 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
101
Ironwood Pharmaceuticals
IRWD
$596M
$949K 0.04%
110,532
– –
TECX
102
Tectonic Therapeutic
TECX
$531M
$331K 0.01%
1,954
-5,546
-74% -$1.26M
AGIO icon
103
CALL
Agios Pharmaceuticals
AGIO
$2.08B
– –
-100,000
Closed -$4.99M
ALNY icon
104
CALL
Alnylam Pharmaceuticals
ALNY
$38.1B
– –
-150,000
Closed -$10.9M
CRSP icon
105
CRISPR Therapeutics
CRSP
$4.63B
– –
-100,000
Closed -$4.71M
CRWD icon
106
CrowdStrike
CRWD
$182B
– –
-400,000
Closed -$6.83M
DNTH icon
107
Dianthus Therapeutics
DNTH
$5.58B
– –
-1,470
Closed -$347K
FTDR icon
108
Frontdoor
FTDR
$5.22B
– –
-100,000
Closed -$4.36M
GM icon
109
CALL
General Motors
GM
$81.2B
– –
-1,000,000
Closed -$38.5M
HTHT icon
110
Huazhu Hotels Group
HTHT
$13.3B
– –
-350,000
Closed -$12.7M
MDGL icon
111
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-35,000
Closed -$3.67M
MLCO icon
112
CALL
Melco Resorts & Entertainment
MLCO
$2.19B
– –
-1,000,000
Closed -$21.7M
NBIX icon
113
CALL
Neurocrine Biosciences
NBIX
$18.2B
– –
-200,000
Closed -$16.9M
NVDA icon
114
CALL
NVIDIA
NVDA
$4.63T
– –
-4,000,000
Closed -$16.4M
RCKT icon
115
Rocket Pharmaceuticals
RCKT
$333M
– –
-360,000
Closed -$5.4M
RCUS icon
116
Arcus Biosciences
RCUS
$3.32B
– –
-270,000
Closed -$2.15M
NGM
117
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-100,000
Closed -$1.46M
CHNG
118
DELISTED
Change Healthcare Inc. Common Stock
CHNG
– –
-750,000
Closed -$10.9M
ALDR
119
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-850,000
Closed -$10M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2019 Portfolio in Review

As of Q3 2019, Artal Group held 119 positions worth $2.49B, up 0.87% from $2.47B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group deployed $155M of net new capital in Q3 2019, opening 16 new positions and adding to 22 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 63% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was NVIDIA, an estimated $37M trimmed.

  • Artal Group's largest Q3 2019 buy was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.
  • Artal Group added most to Morphic Holding, Inc. Common Stock in Q3 2019, an estimated $27.6M increase.
  • Artal Group's biggest Q3 2019 reduction was NVIDIA, cutting an estimated $37M.
  • Artal Group fully exited Huazhu Hotels Group in Q3 2019, selling an estimated $12.7M.
  • Artal Group's ten largest holdings make up 58% of its $2.49B portfolio in Q3 2019.
  • Artal Group opened 16 new positions and closed 17 in Q3 2019.
  • Artal Group's portfolio value rose 0.87% quarter-over-quarter to $2.49B.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.